FibroGen, Inc. (FGEN Quick QuoteFGEN ) along with its Japan-based partner Astellas announced that the European Commission (“EC”) has approved roxadustat to treat adult patients with symptomatic anemia associated with chronic kidney disease (“CKD”). The drug will be sold in Europe under the brand name Evrenzo.
Following approval, Evrenzo is the first orally administered hypoxia-inducible factor-prolyl hydroxylase (“HIF-PH”) inhibitor available in the European Union.
Anemia of CKD is a serious medical condition in which patients have insufficient....More>>>